Ipragliflozin: First global approval

Drugs

Volumn 74, Issue 5, 2014, Pages 611-617

  Poole, Raewyn M ^b   Dungo, Rosselle T ^a  

^a Adis R and D Insight   (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

IPRAGLIFLOZIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; SUGLAT; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSIDE; THIOPHENE DERIVATIVE;

ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAXIMUM PLASMA CONCENTRATION; MILD HEPATIC IMPAIRMENT; MILD RENAL IMPAIRMENT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; DRUG COMBINATION; JAPAN; PATHOPHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG APPROVAL; DRUG THERAPY, COMBINATION; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84900458799     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0204-x     Document Type: Article

References (31)

1. Imamura M, Nakanishi K, Suzuki T, et al. Discovery of ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem. 2012;20(10):3263-79.
2. Veltkamp SA, Kadokura T, Krauwinkel WJJ, et al. Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig. 2011;31(12):839-51.
3. Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep. 2012;12(3):230-8.
4. Misra M. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. J Pharm Pharmacol. 2013;65(3):317-27.
5. Cangoz S, Chang YY, Chempakaseril SJ, et al. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors. J Clin Pharm Ther. 2013;38(5):350-9.
6. Kadokura T, Saito M, Utsuno A, et al. Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetol Int. 2011;2(4):172-82.
7. Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715(1-3):246-55.
8. Astellas Pharma Inc. Approval of Suglat(Rm) tablets, a selective SGLT2 inhibitor for treatment of type 2 diabetes, in Japan. Media Release. 2014
9. Astellas Pharma Inc. R&D Pipeline (November 2012). 2012. http://www.astellas.com/en/ir/library/pdf/2q2013-rd-en.pdf. Accessed.
10. Astellas Pharma Inc. Financial Results for 2Q/FY2012 Ending March 31, 2013. 2012. http://www.astellas.com/en/ir/library/pdf/2q2013pre-en.pdf. Accessed.
11. Astellas Pharma Inc., Msd K.K. Astellas and MSD enter co-promotion agreement in Japan for ipragliflozin, SGLT2 inhibitor for treatment of type 2 diabetes. Media Release. 2013.
12. Tahara A, Kurosaki E, Yokono M, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn-Schmiedebergs Arch Pharmacol. 2012;385(4):423-36.
13. Tahara A, Kurosaki E, Yokono M, et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci. 2012;120(1):36-44.
14. Smulders RA, Leeflang S, Schliess F, et al. The effect of ipragliflozin on the total glucose turnover after OGTT in healthy subjects and patients with type 2 diabetes mellitus. Diabetologia. 2013;56(Suppl):S399-400.
15. Akiyama N, Kashiwagi A, Kadokura T, et al. ASP1941, a novel, selective SGLT2 inhibitor improved both fasting and postprandial glucose levels in Japanese type 2 diabetic patients. Diabetes. 2011;60(Suppl 1):A280-1.
16. Zhang W, Smulders R, Abeyratne A, et al. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study. Clin Ther. 2013;35(8):1150-61.e3.
17. Zhang W, Krauwinkel WJJ, Keirns J, et al. The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor. Clin Drug Investig. 2013;33(7):489-96.
18. Schwartz SL, Akinlade B, Klasen S, et al. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13(12):1219-27.
19. Kadokura T, Ishikawa H, Nakajo I, et al. The effect of renal impairment on the pharmacokinetics and urinary glucose excretion of the SGLT2 inhibitor ipragliflozin (ASP1941) in Japanese type 2 diabetes mellitus patients. Diabetologia. 2011;54:S346.
20. Nakajo I, Taniuchi Y, Yoshida S, et al. Drug interaction study of ipragliflozin and migitol in healthy Japanese subjects. Clin Pharmacol Ther. 2012;91:S11.
21. Zhang W, et al. Lack of pharmacokinetic interactions between Asp1941, a selective sodium glucose co-transporter 2 (Sglt2) inhibitor, and pioglitazone in healthy subjects. Clin Pharmacol Ther. 2011;89(Suppl 1):S82.
22. Smulders RA, Zhang W, Veltkamp SA, et al. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab. 2012;14(10):937-43.
23. Zhang W, et al. Lack of pharmacokinetic interactions between Asp 1941, a selective sodium glucose co-transporter 2 (Sglt2) inhibitor, and sitagliptin in healthy subjects. Clin Pharmacol Ther. 2011;89(Suppl 1):S81-2.
24. Veltkamp SA, Van Dijk J, Krauwinkel WJ, et al. Lack of pharmacokinetic and pharmacodynamic interaction between ipragliflozin, a selective sodium glucose co-transporter 2 (SGLT2) inhibitor, and glimepiride in healthy subjects. Clin Pharmacol Ther. 2012;91:S11-2.
25. Veltkamp SA, van Dijk J, Collins C, et al. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin Ther. 2012;34(8):1761-71.
26. Goto K, Kashiwagi A, Kazuta K, et al. Ipragliflozin reduces A1C and body weight in type 2 diabetes patients who have inadequate glycemic control on metformin alone: Illuminate study. Diabetes. 2012;61:A269.
27. Kashiwagi A, Shiga T, Akiyama N, et al. Ipragliflozin reduced HbA1c and body weight in Japanese type 2 diabetes patients who have inadequate glycaemic control on sulfonylurea or pioglitazone alone. Diabetologia. 2012;55:S302-3.
28. Wilding JPH, Ferrannini E, Fonseca VA, et al. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013;15(5):403-9.
29. Kashiwagi A, Takinami Y, Kazuta K, et al. Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study. Diabetologia. 2011;54:S68-9.
30. Kawano H, Kashiwagi A, Kazuta K, et al. Long-term safety, tolerability and efficacy of ipragliflozin in Japanese patients with type 2 diabetes mellitus: Ignite. Diabetes. 2012;61:A610.
31. Fonseca VA, Ferrannini E, Wilding JP, et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complicat. 2013;27(3):268-73.